These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32096653)

  • 21. Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
    Wei T; Song J; Liang K; Li L; Mo X; Huang Z; Chen G; Mao N; Yang J
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1049-1064. PubMed ID: 33387038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of KIF18A promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma.
    Zhong Y; Jiang L; Lin H; Li X; Long X; Zhou Y; Li B; Li Z
    IUBMB Life; 2019 Jul; 71(7):942-955. PubMed ID: 30817091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
    Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
    J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated expression of
    Feng Z; Zhang J; Zheng Y; Wang Q; Min X; Tian T
    Per Med; 2021 Mar; 18(2):115-127. PubMed ID: 33576264
    [No Abstract]   [Full Text] [Related]  

  • 29. Elevated Expression of
    Hu P; Huang Y; Gao Y; Yan H; Li X; Zhang J; Wang Y; Zhao Y
    DNA Cell Biol; 2020 Apr; 39(4):522-532. PubMed ID: 32040344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
    Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
    J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
    Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
    Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The low expression of NUP62CL indicates good prognosis and high level of immune infiltration in lung adenocarcinoma.
    Ren S; Wang W; Zhang C; Sun Y; Sun M; Wang Y; Zhang X; Lu B; Yao L
    Cancer Med; 2021 May; 10(10):3403-3412. PubMed ID: 33934535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma.
    Hao B; Dong H; Xiong R; Song C; Xu C; Li N; Geng Q
    Comput Biol Med; 2024 Mar; 171():108183. PubMed ID: 38422959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases.
    Zhao J; Guo C; Ma Z; Liu H; Yang C; Li S
    Lung Cancer; 2020 Nov; 149():90-96. PubMed ID: 33002836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
    Chen D; Luo L; Liang C
    PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
    Luo C; Lei M; Zhang Y; Zhang Q; Li L; Lian J; Liu S; Wang L; Pi G; Zhang Y
    J Cell Mol Med; 2020 Jan; 24(2):1233-1244. PubMed ID: 31779055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis.
    Gao Z; Shi R; Yuan K; Wang Y
    Tumour Biol; 2016 Nov; 37(11):14979-14987. PubMed ID: 27655285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.
    Dong M; Yang Z; Li X; Zhang Z; Yin A
    Yonsei Med J; 2020 Dec; 61(12):1013-1023. PubMed ID: 33251775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High
    Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
    Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.